Jennifer Kayden Lee sold $4.4M of RYTM
EVP, Head of North America at RHYTHM PHARMACEUTICALS, INC.. 66,861 shares at an average of $66.33, traded Nov 11, 2024, filed Nov 13, 2024.
Score components
- +15RoleOfficer
- +25Trade size$4.4M at market
- +20Share of holdings soldSold 99% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -8.0%, 3m -4.0%, 6m -4.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-24-117942, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 11, 2024 | MOption exercise Common Stock10b5-1 | +20,622 | $6.80 | $140k | 27,474 | Nov 13, 2024 |
| Nov 11, 2024 | MOption exercise Common Stock10b5-1 | +28,717 | $24.29 | $698k | 56,191 | Nov 13, 2024 |
| Nov 11, 2024 | MOption exercise Common Stock10b5-1 | +11,642 | $30.66 | $357k | 67,833 | Nov 13, 2024 |
| Nov 11, 2024 | SOpen-market sale Common Stock10b5-1 | -38,051 | $65.68 | $2.5M | 29,782 | Nov 13, 2024 |
| Nov 11, 2024 | SOpen-market sale Common Stock10b5-1 | -17,540 | $66.95 | $1.2M | 12,242 | Nov 13, 2024 |
| Nov 11, 2024 | SOpen-market sale Common Stock10b5-1 | -11,070 | $67.56 | $748k | 1,172 | Nov 13, 2024 |
| Nov 11, 2024 | SOpen-market sale Common Stock10b5-1 | -200 | $68.43 | $14k | 972 | Nov 13, 2024 |
| Nov 11, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -20,622 | $0.00 | $0 | 25,790 | Nov 13, 2024 |
| Nov 11, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -28,717 | $0.00 | $0 | 71,283 | Nov 13, 2024 |
| Nov 11, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -11,642 | $0.00 | $0 | 37,108 | Nov 13, 2024 |
Related signals
Other insiders at RHYTHM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | RHYTHM PHARMACEUTICALS, INC. | David P Meeker President and CEO | $5.1M 50,000 shares | -17% | |
| 30Weak | RHYTHM PHARMACEUTICALS, INC. | Hunter C Smith Chief Financial Officer | $6.6M 62,774 shares | -36% | |
| 19Weak | RHYTHM PHARMACEUTICALS, INC. | Christopher Paul German Corporate Controller & CAO | $143k 1,500 shares | -62% | |
| 0Weak | RHYTHM PHARMACEUTICALS, INC. | Pamela J. Cramer Chief Human Resources Officer | $131k 1,520 shares | -7% | |
| 30Weak | RHYTHM PHARMACEUTICALS, INC. | Pamela J. Cramer Chief Human Resources Officer | $1.2M 15,572 shares | -45% | |
| 29Weak | RHYTHM PHARMACEUTICALS, INC. | Christopher Paul German Corporate Controller & CAO | $308k 3,817 shares | -81% | |
| 14Weak | RHYTHM PHARMACEUTICALS, INC. | Alastair Garfield Chief Scientific Officer | $85k 1,319 shares | -30% | |
| 26Weak | RHYTHM PHARMACEUTICALS, INC. | Christopher Paul German Corporate Controller & CAO | $139k 2,069 shares | -52% | |
| 23Weak | RHYTHM PHARMACEUTICALS, INC. | Pamela J. Cramer Chief Human Resources Officer | $478k 7,031 shares | -27% | |
| 40Moderate | RHYTHM PHARMACEUTICALS, INC. | David W J McGirr director | $4.3M 65,431 shares | -96% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.